Under the Radar, BioSig Technologies Inc. (STOCK:BSGM)
Enrolling Patients in Phase II Trials.
Plus News Hit 7-8-2020: ViralClear To Launch Studies of Merimepodib in CV-19
The coronavirus seems to get worse by the day (Source 1).
Months into the global pandemic, the virus has infected just over 11 million people worldwide, killing more than 530,000 (Source 2).
U.S. states are backtracking on reopening plans as cases rise (Source 3). Hospitals are being overwhelmed (Source 4). There’s even fear global economies may need to be shut down again (Source 5).
There is good news.
To combat the coronavirus, the world is turning to the anti-viral drug remdesivir.
So far, the drug has shown improvement in COVID-19 patients in clinical trials and has been cleared for emergency use in severely ill patients in the United States, India South Korea, and in Europe, reports Reuters. (Source 7)
The European Commission just authorized the use of the drug. (Source 8)
“Today’s authorization of a first medicine to treat COVID-19 is an important step forward in the fight against this virus,” EU Health Commissioner Stella Kyriakides said.
The U.S. also just bought 500,000 doses of the Gilead drug, which, according to The Guardian, is all of the company’s production for July, and 90% of its supply for August and September. (Source 9)
But the world may need more than just remdesivir alone.
That’s Where BioSig Technologies Inc. (STOCK:BSGM) Comes into Play
BioSig Technologies could very well hold the key to a successful coronavirus anti-viral drug.
In fact, it and subsidiary ViralClear Pharmaceuticals was just cleared by the US FDA to start a Phase II trial of anti-viral drug merimepodib in COVID-19 patients, along with a combination of Gilead’s successful remdesivir drug.
“The results of these laboratory investigations have strongly influenced our plans for the initial clinical trials of merimepodib. We have experimental evidence that merimepodib is active as monotherapy and in combination with remdesivir,”commented Jerome Zeldis, M.D., Ph.D, Executive Chair and Co-Founder of ViralClear Pharmaceuticals, Inc.
And, according to BioSpace, “Testing the drug with remdesivir immediately elevates the prospects of merimepodib to the top tier of coronavirus drug candidates, as Gilead’s drug is at the forefront of COVID-19 treatment at the moment.”
In preclinical testing, merimepodib – also known as Vicromax – has been found to suppress replication of SARS-CoV-2, the virus that causes COVID-19.
Even better, “Anti-viral medications like Vicromax, however, have an enormous impact. Used as part of a multi-drug cocktail, they have made hepatitis C completely curable, HIV a manageable chronic disease rather than a death sentence, and been very effective against hepatitis B and Ebola,” says a blog found on the BioSig Technologies site.
Symbol: BSGM
Company: BioSig Technologies Inc.
Latest News: https://www.biosig.com/news-media
Company Website: https://www.biosig.com
Catalyst No. 1:
BioSig Technologies (STOCK:BSGM) and ViralClear is Now Enrolling Patients in Phase II Trials
BioSig Technologies and subsidiary, ViralClear Pharmaceuticals just announced patient enrollment with the dosing of the first patient in its Phase II trial for merimepodib.
Confirmed trial sites include three sites from the Mayo Clinic including Rochester, MN, Jacksonville, FL, Phoenix, AZ and St. David’s South Austin Medical Center in Austin, TX and the Atlantic Health System -Overlook Hospital in Summit, NJ and Morristown Medical Center in Morristown, NJ.
To date, preclinical in vitro lab studies performed by the Galveston National Laboratory at The University of Texas Medical Branch demonstrated that merimepodib, provided in combination with remdesivir, showed reduction in SARS-CoV-2 replication to undetectable levels.
Catalyst No. 2:
BioSig Technologies Just Partnered with Catalent (STOCK:BSGM)
Better still, BioSig Technologies and ViralClear just partnered with Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies to develop two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent, merimepodib: a solution and a solid oral dosage form.
Under the terms of the agreement, Catalent will develop two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent, merimepodib: a solution and a solid oral dosage form.
“We are pleased to be working with Catalent that has already manufactured clinical trial materials of our merimepodib oral solution for the current Phase 2 clinical trial and is performing further product development on liquid-filled oral formulations,” commented Steve King, Chief Operating Officer of ViralClear. He continued, “ViralClear is committed to using US-based contract development and manufacturing organizations for the development and commercialization of merimepodib.”
Catalyst No. 3:
BioSig Technologies Also Just Announced Five New Provisional Patent Applications
BioSig also announced that ViralClear Pharmaceuticals filed five new provisional patent applications of its own over the last two months with claims directed to methods of treating or preventing an infectious disease caused by a coronavirus in a human or animal by administering merimepodib, a broad-spectrum anti-viral.
The patents also address methods of inhibiting coronavirus replication in a human or animal by administering merimepodib as a single agent or in combination with other therapeutic agents, e.g., antiviral agents, immune modulators, etc., such as remdesivir, as well as novel oral and IV drug formulations for merimepodib administration.
Catalyst No. 4:
BioSig Technologies (STOCK:BSGM) Has Become Aggressively Oversold
After exploding from a low of $2.36 to $9.45 in recent weeks, shares of BioSig Technologies (STOCK:BSGM) pulled back to $7.40 a share on profit taking. However, now at its 200-day moving average, coupled with over-extensions on RSI, MACD, and Williams’ %R range, the stock has become aggressively oversold.
Investment Highlights for BioSig Technologies Inc. (STOCK:BSGM)
One, BioSig and subsidiary ViralClear Pharmaceuticals could soon piggyback on the success of remdesivir. In fact, the two companies just received US FDA clearance to start a Phase II trial of anti-viral drug merimepodib in COVID-19 patients, along with a combination of Gilead’s successful remdesivir drug.
Two, “Testing the drug with remdesivir immediately elevates the prospects of merimepodib to the top tier of coronavirus drug candidates, as Gilead’s drug is at the forefront of COVID-19 treatment at the moment.”
Three, in preclinical testing, merimepodib – also known as Vicromax – has been found to suppress replication of SARS-CoV-2, the virus that causes COVID-19.
Four, BioSig Technologies and ViralClear just partnered with Catalent, which will develop two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent, merimepodib: a solution and a solid oral dosage form.
Five, BioSig Technologies (STOCK:BSGM) has become aggressively oversold at its 200-day moving average with technical confirmation from RSI, MACD, and Williams’ %R.
Source 1: https://www.nytimes.com/2020/07/04/health/coronavirus-death-rate.html
Source 2: https://coronavirus.jhu.edu/us-map
Source 3: https://www.nytimes.com/2020/06/27/world/coronavirus-updates.html
Source 4: https://people.com/health/texas-doctor-forced-to-choose-which-covid-19-patients-get-beds/
Source 8: https://www.timesofisrael.com/eu-authorizes-use-of-remdesivir-to-treat-coronavirus/
Source 9: https://www.theguardian.com/us-news/2020/jun/30/us-buys-up-world-stock-of-key-covid-19-drug
Pursuant to an agreement between TD Media LLC and Legends Media LLC TD Media LLC has been hired for a period beginning on 7/6/20 and ending on 7/10/20 to publicly disseminate information about (BSGM) via digital communications. We have been paid twelve thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM)